Carcinoid syndrome and valvular heart disease: A national perspective on patient characteristics and cardiovascular outcomes. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This ...
Complete SAFE KIDNEY II data confirm sustained reduction in viral load and resolution of biopsy-proven BKPyV-associated nephropathy with continued antiviral effect to 38 weeks Systematic literature ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results